New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide magnesium stearate mannitol pregelatinised maize starch starch - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg;  ;  ;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg       excipient: calcium hydrogen phosphate dihydrate ferric oxide red (ci77491) magnesium stearate maize starch mannitol - lisinopril is indicated in the treatment of essential hypertension and in renovascular hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to 10 mg lisinopril   excipient: calcium hydrogen phosphate dihydrate magnesium stearate maize starch mannitol purified talc

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 21.78 mg - tablet - excipient ingredients: croscarmellose sodium; mannitol; maize starch; magnesium stearate; iron oxide red; calcium hydrogen phosphate dihydrate - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 10.89 mg - tablet - excipient ingredients: mannitol; iron oxide red; maize starch; magnesium stearate; calcium hydrogen phosphate dihydrate; croscarmellose sodium - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - lisinopril dihydrate, quantity: 5.44 mg - tablet - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; magnesium stearate; croscarmellose sodium; iron oxide red - 1.hypertension: lisinopril is indicated for the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. 2. congestive heart failure: lisinopril is also indicated for the treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. 3. acute myocardial infarction: lisinopril is indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg excipient: calcium hydrogen phosphate dihydrate colloidal silicon dioxide iron oxide red magnesium stearate maize starch mannitol starch

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: magnesium stearate; iron oxide red; colloidal anhydrous silica; mannitol; maize starch; calcium hydrogen phosphate dihydrate; pregelatinised maize starch - hypertension. lisinopril generic health tablets are indicated in the treatment of hypertension. it may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure lisinopril generic health tablets are also indicated in the treatment of heart failure. in such patients, it is recommended that lisinopril generic health tablets be administered together with a diuretic. acute myocardial infarction: lisinopril generic health tablets are indicated for the treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.

New Zealand - English - Medsafe (Medicines Safety Authority)

ipca pharma (nz) pty limited - lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg;  ;  ;   - tablet - 10 mg - active: lisinopril dihydrate 10.89mg equivalent to lisinopril 10 mg       excipient: calcium hydrogen phosphate dihydrate ferric oxide red (ci77491) magnesium stearate maize starch mannitol

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lisinopril dihydrate, quantity: 10.89 mg (equivalent: lisinopril, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; mannitol; maize starch; pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica - hypertension: treatment of hypertension. lisinopril may be used alone or concomitantly with other classes of antihypertensive agents. sufficient data have not been provided to support the use of lisinopril in severe hypertension or renovascular hypertension. congestive heart failure: treatment of heart failure. in such patients, it is recommended that lisinopril be administered together with a diuretic. acute myocardial infarction: treatment of acute myocardial infarction in haemodynamically stable patients, defined as patients who are not in cardiogenic shock and who have a systolic blood pressure greater than 100 mmhg. lisinopril may be initiated within 24 hours of an acute myocardial infarction.